Management impact of FDG-PET in dementia: Results from a tertiary center memory clinic

Journal of Alzheimer's Disease

Volumn 42, Issue 3, 2014, Pages 885-892

  Elias, Alby ^a   Woodward, Michael ^b   Rowe, Christopher C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Alzheimer's disease; diagnostic impact; FDG PET; memory clinic

Indexed keywords

CHOLINESTERASE INHIBITOR; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BRAIN REGION; CLINICAL ASSESSMENT; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRESCRIPTION; PROSPECTIVE STUDY; TERTIARY CARE CENTER; APHASIA; BRAIN; CHI SQUARE DISTRIBUTION; CLASSIFICATION; DIAGNOSTIC USE; LONGITUDINAL STUDY; MENTAL HEALTH; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; APHASIA; BRAIN; CHI-SQUARE DISTRIBUTION; DEMENTIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS;

EID: 84907155530     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132729     Document Type: Article

References (40)

1. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, van Belle Jolley, Larson EB (2002) Dementia and Alzheimer disease incidence: A prospective cohort study. Arch Neurol 59, 1737-1746.
2. Brookmeyer R, Johnson E, Ziegler-Graha K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3, 186-191.
3. Villemagne VL, BurnhamS, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 12, 357-367.
4. Jack CR Jr, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, Pankratz VS, Senjem ML, Gunter JL, Mielke MM, Lowe VJ, Boeve BF, Petersen RC (2013) Brain-amyloid load approaches a plateau. Neurology 80, 890-896.
5. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
6. Beach TG, Monsell SE, Phillips LE, KukullW(2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 71, 266-273.
7. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC (2001) Practice parameter: Diagnosis of dementia (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1143-1153.
8. Birks J, Iakovidou V, Tsolaki M (2000) Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. In: The Cochrane Library. 2000;4:CD001191. Available from: Update Software Ltd., Oxford, U.K. Accessed August, 30, 2000.
9. Small GW, Donohue JA, Brooks RL (1998) An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Ther 20, 838-850.
10. Silverman DH, Gambhir SS, Huang HW, Schwimmer J, Kim S, SmallGW, Chodosh J, Czernin J, PhelpsME(2002) Evaluating early dementia with and without assessment of regional cerebral metabolism by PET:Acomparison of predicted costs and benefits. J Nucl Med 43, 253-266.
11. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
12. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9, 1118-1127.
13. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G,Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
14. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
15. Silverman DHS, Small GW, Chang CY, Lu CS, Kung Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME (2001) Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286, 2120-2127.
16. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, KuhlDE(1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 42, 85-94.
17. Lim SM, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, Bradshaw J, Merory J,Woodward M, Hopwood M, Rowe CC (2009) The 18F-FDG PET cingulate island sign and comparison to 123I-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 50, 1638-1645.
18. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL,Kuhl DE (2001) Alzheimer's dementia versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation. Ann Neurol 50, 358-365.
19. Kanda T, Ishii K, Uemura T, Miyamoto N,Yoshikawa T,Kono AK, Mori E (2008) Comparison of grey matter and metabolic reductions in frontotemporal dementia using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging 35, 2227-2234.
20. Diehl J, Grimmer T, Drzezga A, Riemenschneider M, Förstl H, Kurz A (2004) Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia. A PET study. Neurobiol Aging 25, 1051-1056.
21. Perneczky R, Diehl-Schmid J, Pohl C, Drzezga A, Kurz A (2007) Non-fluent progressive aphasia: Cerebral metabolic patterns and brain reserve. Brain Res 1133, 178-185.
22. Blin J, Vidailhet MJ, Pillon B, Dubois B, Feve JR, Agid Y (1992) Corticobasal degeneration: Decreased and asymmetrical glucose consumption as studied with PET. Mov Disord 7, 348-354.
23. Bohnen NI, Djang DS, Herholz K, Anzai Y, Minoshima S (2012) Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: A review of the recent literature. J Nucl Med 53, 59-71.
24. Jagust W, Reed B, Mungas D, Ellis W, Decarli C (2007) What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69, 871-877.
25. Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, Turner RS, Koeppe RA, Higdon R, Minoshima S (2007) FDG-PET improves accuracy in distinguishing frontal temporal dementia and Alzheimer's disease. Brain 130, 2616-2635.
26. Moulin-Rosmee G, Maes A, Silverman D, Mortelmans L, Van Laere K (2005) Cost-effectiveness of 18Ffluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective. Eur J Neurol 12, 254-263.
27. Wippold FJ II, Cornelius RS, BroderickDF, Brown DC, Brunberg JA, Davis PC, De La Paz RL, Frey KA, Garvin CF, Holloway K, McConnell CT Jr, Mukherji SK, Rosenow JM, Seidenwurm DJ, Slavin K, Sloan MA, Smirniotopoulos JG, Expert Panel on Neurologic Imaging. ACR Appropriateness Criteria® dementia and movement disorders. [online publication] Reston (VA): American College of Radiology (ACR); 2010. 14p.
28. Silverman DHS (2004) Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: Comparison with perfusion SPECT and clinical evaluations lacking nuclear imaging. J Nuc Med 45, 594-607.
29. Laforce R, Buteau JP, Paquet N,Verret L, Houde M, Bouchard RW (2010) The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: A retrospective memory clinic study. Am J Alzheimers Dis Other Dement 25, 324-332.
30. Ossenkoppele R, Prins ND, Pijnenburg YAL, Lemstra AW, van der Flier WM, Adriaanse SF, Windhorst AD, Handels RLH,Wolfs CAG, P, Verhey FRJ, Verbeek MM, van Buchem MA,Hoekstra OS, Lammertsma AA, Scheltens P, van Berckel BNM (2013) Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement 9, 414-421.
31. Coyle J, Kershaw P (2001) Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease. Biol Psychiatry 49, 289-299.
32. Rogers SL, Doody RS, Pratt RD, Leni JR (2000) Longterm efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre openlabel study. Eur Neuropsychopharmacol 10, 195-203.
33. Hernandez RK, Farwell W, Cantor MD, Lawler EV (2000) Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs New England healthcare system. J Am Geriatr Soc 57, 1997-2003.
34. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand SL, Rochon PA (2009) Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: A population-based cohort study. Arch Intern Med 169, 867-873.
35. Mendez MF, Shapira JS, McMurtray A, Licht E (2007) Reported a worsening of disinhibition and compulsive behaviors in patients with FTD in conjunction with donepezil treatment, highlighting a possible adverse reaction to the medication. Am J Geriatr Psychiatry 15, 84-87.
36. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E (1992) Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 305, 673-678.
37. Nelson PT, Jicha GA, Kryscio RJ, Abner EL, Schmitt FA, Cooper G, Xu LO, Smith CD, Markesbery WR (2010) Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 257, 359-366.
38. Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, Ince PG, Perry R, McKeith I, Katona CL (2007) Dementia with Lewy bodies: A comparison of clinical diag nosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 78, 1176-1181.
39. Alzheimer's Association (2014) Alzheimer's and Dementia testing for early diagnosis, http://www.alz.org/research/science/earlier alzheimers diagnosis.asp
40. Johnson KA, Minoshima S, Bohnen NI (2013) Appropriate use criteria for amyloid PET:Areport of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med 54, 476-490.